达雷妥尤单抗用于初始治疗后早期或晚期复发的骨髓瘤患者:CASTOR和POLLUX研究的亚组分析
该研究为CASTOR和POLLUX两项3期研究的事后亚组分析,评估达雷妥尤单抗联合方案对比单纯Vd/Rd在仅接受过一线治疗且按首次治疗后进展/复发时间(早期或晚期)分组的复发/难治性多发性骨髓瘤患者中的疗效。结果显示,无论采用24个月还是18个月作为早期复发界值,含达雷妥尤单抗方案的无进展生存期在各亚组中均一致占优;采用24个月界值时,早期复发组和晚期复发组疾病进展或死亡风险均降低65%;总生存期在两组中亦均 favoring 含达雷妥尤单抗方案。尽管达雷妥尤单抗无法完全克服早期复发的不良预后,结果支持对仅接受过一线治疗的患者(包括早期进展/复发且被视为功能性高危者)使用达雷妥尤单抗。
要点
- 无论采用24个月还是18个月作为早期复发界值,含达雷妥尤单抗方案的无进展生存期在各亚组中均一致占优。
- 采用24个月界值时,早期复发组(<24个月)和晚期复发组(≥24个月)疾病进展或死亡风险均降低65%(HR均为0.35)。
- 采用24个月界值时,总生存期在早期复发组(HR 0.62)和晚期复发组(HR 0.67)中均 favoring 含达雷妥尤单抗方案。
核心结论
- 尽管达雷妥尤单抗无法完全克服早期复发的不良预后,结果支持对仅接受过一线治疗的患者(包括早期进展/复发且被视为功能性高危多发性骨髓瘤者)使用达雷妥尤单抗。
研究设计与样本
- CASTOR和POLLUX两项3期研究的事后亚组分析。
主要发现
- 在CASTOR/POLLUX汇总数据集中,采用24个月界值时,早期复发组(<24个月)疾病进展或死亡风险降低65%(HR 0.35;95%CI 0.26-0.48;P<.0001),晚期复发组(≥24个月)疾病进展或死亡风险降低65%(HR 0.35;95%CI 0.26-0.47;P<.0001)。
- 采用24个月界值时,汇总人群中早期复发组总生存期HR 0.62(95%CI 0.45-0.86;P=.0036),晚期复发组总生存期HR 0.67(95%CI 0.48-0.93;P=.0183),均 favoring 含达雷妥尤单抗方案。
- 无论进展/复发时机如何,达雷妥尤单抗组的≥完全缓解率和微小残留病阴性率(10⁻⁵)均高于对照组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-risk multiple myeloma (MM) is often defined based on cytogenetic abnormalities, but patients who relapse early after initial therapy are considered a functional high-risk group. In the phase 3 CASTOR and POLLUX studies, daratumumab plus bortezomib/dexamethasone (D-Vd) or lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS), regardless of cytogenetic risk, and achieved higher rates of complete response or better (≥CR) and minimal residual disease (MRD) negativity vs that with Vd/Rd alone in relapsed/refractory MM. Post hoc analyses of CASTOR and POLLUX evaluated patient subgroups with 1 prior line of therapy based on timing of progression/relapse (early or late) after initiation of first line of therapy. PFS consistently favored the daratumumab-containing regimens across subgroups using both a 24- and 18-month early-relapse cutoff. In the CASTOR/POLLUX pooled data set, daratumumab reduced the risk of disease progression or death by 65% (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.26-0.48; P < .0001) in the early-relapse (<24 months) subgroup and by 65% (HR, 0.35; 95% CI, 0.26-0.47; P < .0001) in the late-relapse (≥24 months) subgroup. OS also favored the daratumumab-containing regimens in both the early-relapse (HR, 0.62; 95% CI, 0.45-0.86; P = .0036) and late-relapse (HR, 0.67; 95% CI, 0.48-0.93; P = .0183) subgroups in the pooled population using a 24-month cutoff. Rates of ≥CR and MRD negativity (10-5) were higher with daratumumab vs control, regardless of progression/relapse timing. Although daratumumab is unable to fully overcome the adverse prognosis of early relapse, our results support the use of daratumumab for patients with 1 prior line of therapy, including for those who progress/relapse early after initial therapy and are considered to have functional high-risk MM. These trials were registered at www.clinicaltrials.gov as #NCT02136134 (CASTOR) and #NCT02076009 (POLLUX).
引用
- Spencer A, Moreau P, Mateos MV, et al. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Adv. 2024. PMID: 38048391. doi:10.1182/bloodadvances.2023010579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。